Glycemic Variability: Assessing Glycemia Differently and the Implications for Dietary Management of Diabetes

Annual Review of Nutrition

Volumn 35, Issue 1, 2015, Pages 389-424

  Tay, Jeannie ^a,b,c   Thompson, Campbell H ^b   Brinkworth, Grant D ^a  

^a CSIRO   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c AGENCY FOR SCIENCE   (Singapore)

Author keywords

Diabetes; Diet; Glycemic control; Nutrition; Postprandial

Indexed keywords

CARBOHYDRATE; GLUCOSE; HEMOGLOBIN A1C; PROTEIN; CARBOHYDRATE DIET; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PROTEIN INTAKE;

AREA UNDER THE CURVE; BLOOD GLUCOSE MONITORING; CARBOHYDRATE INTAKE; DIABETES MELLITUS; DIET; DIET RESTRICTION; DIETARY FIBER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; GLYCEMIC VARIABILITY; HUMAN; HYPOGLYCEMIA; METABOLIC PARAMETERS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW; ADMINISTRATION AND DOSAGE; ANALYSIS; BLOOD; CARBOHYDRATE DIET; CARDIOVASCULAR DISEASE; DIET THERAPY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PHYSIOLOGY; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIET; DIETARY CARBOHYDRATES; DIETARY FIBER; DIETARY PROTEINS; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OXIDATIVE STRESS; RISK FACTORS;

EID: 84937573135     PISSN: 01999885     EISSN: 15454312     Source Type: Book Series    
DOI: 10.1146/annurev-nutr-121214-104422     Document Type: Review

References (241)

1. Action Control Cardiovasc. Risk Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, et al. 2008. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J.Med. 358:2545-59
2. ADVANCE Collab. Group, Patel A, MacMahon S, Chalmers J, Neal B, et al. 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358:2560-72
3. Akhavan T, Luhovyy BL, Brown PH, Cho CE, Anderson GH. 2010. Effect of premeal consumption of whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults. Am. J. Clin. Nutr. 91:966-75
4. Am. Diabetes Assoc. 2001. Postprandial blood glucose. American Diabetes Association. Diabetes Care 24:775-78
5. Am. Diabetes Assoc. 2013. Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl. 1):S67-74
6. Am. Diabetes Assoc. 2013. Standards of medical care in diabetes-2013. Diabetes Care 36(Suppl. 1):S11-66
7. Am. Diabetes Assoc, Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, et al. 2008. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 31(Suppl. 1):S61-78
8. Amori RE, Lau J, Pittas AG. 2007. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194-206
9. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, et al. 2006. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632-37
10. Avignon A, Radauceanu A, Monnier L. 1997. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20:1822-26
11. Avogaro A. 2011. Postprandial glucose: marker or risk factor? Diabetes Care 34:2333-35
12. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. 1999. Is there a glycemic threshold for mortality risk? Diabetes Care 22:696-99
13. Barbieri M, Rizzo MR,Marfella R, Boccardi V, Esposito A, et al. 2013. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 227:349-54
14. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, et al. 1999. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354:622-25
15. Bastyr EJ 3rd, Stuart CA, Brodows RG, Schwartz S, Graf CJ, et al. 2000. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 23:1236-41
16. Bessard J, Cracowski JL, Stanke-Labesque F, Bessard G. 2001. Determination of isoprostaglandin F2α type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. J. Chromatogr. B Biomed. Sci. Appl. 754:333-43
17. Bibra HV, Siegmund T, Ceriello A, Volozhyna M, Schumm-Draeger PM. 2009. Optimized postprandial glucose control is associated with improved cardiac/vascular function-comparison of three insulin regimens in well-controlled type 2 diabetes. Horm. Metab. Res. 41:109-15
18. Bode BW, Schwartz S, Stubbs HA, Block JE. 2005. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 28:2361-66
19. Boirie Y, Dangin M, Gachon P, Vasson MP, Maubois JL, Beaufrere B. 1997. Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc. Natl. Acad. Sci. USA 94:14930-35
20. BondsDE, MillerME, Bergenstal RM, Buse JB, Byington RP, et al. 2010. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909
21. Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, et al. 2001. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 24:2023-29
22. Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, et al. 2006. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 49:846-54
23. Borch-Johnsen K, Neil A, Balkau B, Larsen S, Nissinen A, et al. 2001. Glucose tolerance and cardiovascular mortality-comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 161:397-405
24. Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan DM, et al. 2010. Associations between features of glucose exposure and A1C: the A1C-Derived Average Glucose (ADAG) Study. Diabetes 59:1585-90
25. Bouma M, Dekker JH, de Sonnaville JJ, van der Does FE, de Vries H, et al. 1999. How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes? Diabetes Care 22:904-7
26. Bragd J, Adamson U, Backlund LB, Lins PE, Moberg E, Oskarsson P. 2008. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab. 34:612-16
27. Brand-Miller JC, Thomas M, Swan V, Ahmad ZI, Petocz P, Colagiuri S. 2003. Physiological validation of the concept of glycemic load in lean young adults. J. Nutr. 133:2728-32
28. Brasacchio D, Okabe J,Tikellis C, Balcerczyk A,George P, et al. 2009. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58:1229-36
29. Brownlee M. 2005. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-25
30. BrownleeM,Hirsch IB. 2006. Glycemic variability: a hemoglobinA1c-independent risk factor for diabetic complications. JAMA 295:1707-8
31. Brynes AE, Lee JL, Brighton RE, Leeds AR, Dornhorst A, Frost GS. 2003. A low glycemic diet significantly improves the 24-h blood glucose profile in people with type 2 diabetes, as assessed using the continuous glucose MiniMed monitor. Diabetes Care 26:548-49
32. Brynes AE, Edwards CM, Ghatei MA, Dornhorst A, Morgan LM, et al. 2003. A randomised fourintervention crossover study investigating the effect of carbohydrates on daytime profiles of insulin, glucose, non-esterified fatty acids and triacylglycerols in middle-aged men. Br. J. Nutr. 89:207-18
33. Bunn HF, Gabbay KH, Gallop PM. 1978. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200:21-27
34. Bunn HF,Haney DN, Kamin S, Gabbay KH, Gallop PM. 1976. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J. Clin. Invest. 57:1652-59
35. Buscemi S, Cosentino L, Rosafio G, MorganaM,Mattina A, et al. 2013. Effects of hypocaloric diets with different glycemic indexes on endothelial function and glycemic variability in overweight and in obese adult patients at increased cardiovascular risk. Clin. Nutr. 32:346-52
36. Buscemi S, Re A, Batsis JA, Arnone M, Mattina A, et al. 2010. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in type 2 diabetes. Diabet Med. 27:872-78
37. Cameron FJ, Donath SM, Baghurst PA. 2010. Measuring glycaemic variation. Curr. Diabetes Rev. 6:17-26
38. Campbell PJ, Mandarino LJ, Gerich JE. 1988. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism 37:15-21
39. Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade DS. 2003. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. J. Clin. Endocrinol. Metab. 88:5248-54
40. Cavalot F, Pagliarino A, Valle M, Di Martino L, Bonomo K, et al. 2011. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 34:2237-43
41. Ceriello A. 2005. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 54:1-7
42. Ceriello A. 2009. Postprandial hyperglycemia and cardiovascular disease: Is the HEART2D study the answer? Diabetes Care 32:521-22
43. Ceriello A. 2010. The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int. J. Clin. Pract. 64:1705-11
44. Ceriello A. 2010. Point: Postprandial glucose levels are a clinically important treatment target. Diabetes Care 33:1905-7
45. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, et al. 2004. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet. Med. 21:171-75
46. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J, Guidel. Dev. Group. 2008. Guideline for management of postmeal glucose. Nutr. Metab. Cardiovasc. Dis. 18:S17-33
47. Ceriello A, Davidson J, Hanefeld M, Leiter L, Monnier L, et al. 2006. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr. Metab. Cardiovasc. Dis. 16:453-56
48. Ceriello A, EspositoK, IhnatM,Thorpe J,GiuglianoD. 2010. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in type 1 diabetic patients with different characteristics. Diabet. Med. 27:911-17
49. Ceriello A, Esposito K, Piconi L, Ihnat M, Thorpe J, et al. 2008. Glucose "peak" and glucose "spike": impact on endothelial function and oxidative stress. Diabetes Res. Clin. Pract. 82:262-67
50. Ceriello A, EspositoK,Piconi L, IhnatMA, Thorpe JE, et al. 2008. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57:1349-54
51. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, et al. 2004. Postprandial glucose regulation and diabetic complications. Arch. Intern. Med. 164:2090-95
52. Ceriello A, Ihnat MA. 2010. "Glycaemic variability": a new therapeutic challenge in diabetes and the critical care setting. Diabet. Med. 27:862-67
53. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, et al. 2002. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25:1439-43
54. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, et al. 2004. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53:701-10
55. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, et al. 2002. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation 106:1211-18
56. Chandalia M, Garg A, Lutjohann D, von Bergmann K,Grundy SM, Brinkley LJ. 2000. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N. Engl. J. Med. 342:1392-98
57. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, et al. 2003. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-94
58. Chittari MV, McTernan P, Bawazeer N, Constantinides K, Ciotola M, et al. 2011. Impact of acute hyperglycaemia on endothelial function and retinal vascular reactivity in patients with type 2 diabetes. Diabet. Med. 28:450-54
59. Coutinho M, Gerstein HC, Wang Y, Yusuf S. 1999. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-40
60. Dahl JH, van Breemen RB. 2010. Rapid quantitative analysis of 8-iso-prostaglandin-F2α using liquid chromatography-tandem mass spectrometry and comparison with an enzyme immunoassay method. Anal. Biochem. 404:211-16
61. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, et al. 2001. Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an antiinflammatory effect? J. Clin. Endocrinol. Metab. 86:3257-65
62. Dandona P, Chaudhuri A,GhanimH,Mohanty P. 2009. Insulin as an anti-inflammatory and antiatherogenic modulator. J. Am. Coll. Cardiol. 53:S14-20
63. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, et al. 1999. In vivo formation of 8-isoprostaglandin F2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224-29
64. Davi G, Falco A, Patrono C. 2005. Lipid peroxidation in diabetes mellitus. Antioxid. Redox Signal. 7:256-68
65. De Natale C, Annuzzi G, Bozzetto L, Mazzarella R, Costabile G, et al. 2009. Effects of a plant-based highcarbohydrate/ high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. Diabetes Care 32:2168-73
66. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, et al. 1999. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42:926-31
67. Derr R, Garrett E, Stacy GA, Saudek CD. 2003. Is HbA1c affected by glycemic instability? Diabetes Care 26:2728-33
68. Devaraj S, Hirany SV, Burk RF, Jialal I. 2001. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin. Chem. 47:1974-79
69. Di Flaviani A, Picconi F, Di Stefano P, Giordani I, Malandrucco I, et al. 2011. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care 34:1605-9
70. Dinneen S, Gerich J, Rizza R. 1992. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 327:707-13
71. Donahue RP, Abbott RD, Reed DM, Yano K. 1987. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36:689-92
72. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, et al. 2009. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360:129-39
73. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. 2006. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 105:244-52
74. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, et al. 2008. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205:2409-17
75. Esposito K, Ciotola M, Carleo D, Schisano B, Sardelli L, et al. 2008. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 93:1345-50
76. Esposito K, Giugliano D, Nappo F, Marfella R, Campanian Postprandial Hyperglycemia Study Group. 2004. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214-19
77. Esposito K,Nappo F, Marfella R, GiuglianoG,Giugliano F, et al. 2002. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067-72
78. EvertAB, Boucher JL, CypressM,Dunbar SA, FranzMJ, et al. 2013. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 36:3821-42
79. Fabricatore AN, EbbelingCB, WaddenTA, Ludwig DS. 2011. Continuous glucosemonitoring to assess the ecologic validity of dietary glycemic index and glycemic load. Am. J. Clin. Nutr. 94:1519-24
80. Festa A, Williams K, Hanley AJ, Haffner SM. 2008. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638-44
81. Fiallo-Scharer R, Diabetes Res. Child. Netw. Study Group. 2005. Eight-point glucose testing versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. J. Clin. Endocrinol. Metab. 90:3387-91
82. Folli F, Guzzi V, Perego L, Coletta DK, Finzi G, et al. 2010. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients skin which are normalized by kidney-pancreas transplantation. PLOS ONE 5:e9923
83. Frid AH, Nilsson M, Holst JJ, Bj orck IM. 2005. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am. J. Clin. Nutr. 82:69-75
84. Frier BM, Schernthaner G, Heller SR. 2011. Hypoglycemia and cardiovascular risks. Diabetes Care 34(Suppl. 2):S132-37
85. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. 1980. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1:1373-76
86. GannonMC, Nuttall FQ. 2004. Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. Diabetes 53:2375-82
87. Gannon MC, Nuttall FQ. 2010. Amino acid ingestion and glucose metabolism-A review. IUBMB Life 62:660-68
88. Gannon MC, Nuttall FQ, Lane JT, Burmeister LA. 1992. Metabolic response to cottage cheese or egg white protein, with or without glucose, in type II diabetic subjects. Metabolism 41:1137-45
89. Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H. 2003. An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am. J. Clin. Nutr. 78:734-41
90. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, et al. 2002. Metabolic effects of visceral fat accumulation in type 2 diabetes. J. Clin. Endocrinol. Metab. 87:5098-103
91. Giacco R, Parillo M, Rivellese AA, Lasorella G, Giacco A, et al. 2000. Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. Diabetes Care 23:1461-66
92. Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM. 2003. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J. Diabetes Complications 17:78-81
93. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. 2011. Efficacy of insulin analogs in achieving the hemoglobin A1c target of 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 34:510-17
94. Gordin D, Ronnback M, Forsblom C, Makinen V, Saraheimo M, Groop PH. 2008. Glucose variability, blood pressure and arterial stiffness in type 1 diabetes. Diabetes Res. Clin. Pract. 80:e4-7
95. Gribble FM, Manley SE, Levy JC. 2001. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 24:1221-25
96. Grover-Paez F, Zavalza-Gomez AB. 2009. Endothelial dysfunction and cardiovascular risk factors. Diabetes Res. Clin. Pract. 84:1-10
97. Gunnerud UJ, Heinzle C, Holst JJ, Ostman EM, Bj orck IM. 2012. Effects of pre-meal drinks with protein and amino acids on glycemic and metabolic responses at a subsequent composite meal. PLOS ONE 7:e44731
98. Gunnerud UJ, Ostman EM, Bj orck IM. 2013. Effects of whey proteins on glycaemia and insulinaemia to an oral glucose load in healthy adults; a dose-response study. Eur. J. Clin. Nutr. 67:749-53
99. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. 2004. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur. Heart J. 25:10-16
100. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. 2004. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35:1073-78
101. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, et al. 1996. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-83
102. Hanefeld M, KoehlerC, Schaper F, FueckerK,HenkelE,Temelkova-Kurktschiev T. 1999. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144:229-35
103. Hernandez TL, Van Pelt RE, AndersonMA, Daniels LJ, West NA, et al. 2014. A higher-complex carbohydrate diet in gestational diabetes achieves glucose targets and lowers postprandial lipids: a randomized crossover study. Diabetes Care 37:1254-62
104. Hirsch IB. 2005. Glycemic variability: It s not just about A1C anymore! Diabetes Technol. Ther. 7:780-83
105. Hirsch IB, BrownleeM. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic microvascular complications. JAMA 303:2291-92
106. Holman RR, Paul SK, BethelMA, MatthewsDR, Neil HA. 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359:1577-89
107. Ihnat MA, Kaltreider RC, Thorpe JE, Green DE, Kamat CD. 2007. Attenuated superoxide dismutase induction in retinal cells in response to intermittent high versus continuous high glucose.Am. J. Biochem. Biotechnol. 3:16-23
108. Ihnat MA, Thorpe JE, Ceriello A. 2007. Hypothesis: the "metabolic memory," the new challenge of diabetes. Diabet. Med. 24:582-86
109. Intl. Diabetes Fed. 2011. Guideline for Management of Postmeal Glucose in Diabetes. Brussels: Intl. Diabetes Fed
110. Intl. Diabetes Fed. 2013. IDF Diabetes Atlas. Brussels: Intl. Diabetes Fed. 6th ed. http://www.idf.org/ diabetesatlas
111. Intl. Expert Comm. 2009. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327-34
112. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. 2012. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364-79
113. Jakubowicz D, Froy O, Ahren B, Boaz M, Landau Z, et al. 2014. Incretin, insulinotropic and glucoselowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial. Diabetologia 57:1807-11
114. Jarvi AE, Karlstrom BE, Granfeldt YE, Bj orck IE, ASP NG, Vessby BO. 1999. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. Diabetes Care 22:10-18
115. Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, et al. 1981. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am. J. Clin. Nutr. 34:362-66
116. Juv. Diabetes Res. Found. Contin.Glucose Monit. Study Group, TamborlaneWV, BeckRW, Bode BW, Buckingham B, et al. 2008. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N. Engl. J. Med. 359:1464-76
117. Kang X,WangC, Lifang L, Chen D, Yang Y, et al. 2013. Effects of different proportion of carbohydrate in breakfast on postprandial glucose excursion in normal glucose tolerance and impaired glucose regulation subjects. Diabetes Technol. Ther. 15:569-74
118. Kawano H, Motoyama T, HirashimaO,Hirai N, Miyao Y, et al. 1999. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J. Am. Coll. Cardiol. 34:146-54
119. Kilpatrick ES, Rigby AS, Atkin SL. 2006. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486-90
120. Kilpatrick ES, Rigby AS, Atkin SL. 2008. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 31:2198-202
121. Kilpatrick ES, Rigby AS, Atkin SL. 2008. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 51:365-71
122. Kilpatrick ES, Rigby AS, Atkin SL. 2009. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901-3
123. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. 2007. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 50:2553-61
124. Kitabchi AE, Kaminska E, Fisher JN, Sherman A, Pitts K, et al. 2000. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. Am. J. Med. Sci. 319:143-48
125. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, et al. 2004. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 27:2067-73
126. Klonoff DC. 2005. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28:1231-39
127. KovatchevBP, Cox DJ, FarhyLS, StraumeM,Gonder-Frederick L, ClarkeWL.2000. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J. Clin. Endocrinol. Metab. 85:4287-92
128. Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL. 2003. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol. Ther. 5:817-28
129. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. 2006. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 29:2433-38
130. Krinsley JS. 2008. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit. Care Med. 36:3008-13
131. Kudva YC, Basu A, Jenkins GD, Pons GM, Vogelsang DA, et al. 2007. Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin. Endocr. Pract. 13:244-50
132. Kuenen JC, Borg R, Kuik DJ, Zheng H, Schoenfeld D, et al. 2011. Does glucose variability influence the relationship between mean plasma glucose and HbA1c levels in type 1 and type 2 diabetic patients? Diabetes Care 34:1843-47
133. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, DCCT/EDIC Group. 2008. Effect of glycemic exposure on the risk of microvascular complications in theDiabetes Control and Complications Trial-revisited. Diabetes 57:995-1001
134. Lawson JA, Rokach J, FitzGerald GA. 1999. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 274:24441-44
135. Levitan EB, Song Y, Ford ES, Liu S. 2004. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch. Intern. Med. 164:2147-55
136. Lin CC, Li CI, Yang SY, Liu CS, Chen CC, et al. 2012. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am. J. Med. 125:416.e9-18
137. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. 1997. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 20:163-69
138. Lu ZX,Walker KZ,Muir JG, O Dea K. 2004. Arabinoxylan fibre improves metabolic control in people with type II diabetes. Eur. J. Clin. Nutr. 58:621-28
139. Ma J, Stevens JE, Cukier K, Maddox AF,Wishart JM, et al. 2009. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 32:1600-2
140. Magnoni D, Rouws CH, Lansink M, van Laere KM, Campos AC. 2008. Long-term use of a diabetesspecific oral nutritional supplement results in a low-postprandial glucose response in diabetes patients. Diabetes Res. Clin. Pract. 80:75-82
141. Malmberg K. 1997. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512-15
142. Mann J. 2001. Dietary fibre and diabetes revisited. Eur. J. Clin. Nutr. 55:919-21
143. Mann JI, De Leeuw I,Hermansen K, Karamanos B, Karlstrom B, et al. 2004. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr.Metab. Cardiovasc. Dis. 14:373-94
144. Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB. 2011. A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care 34:1011-13
145. Maurizi AR, Pozzilli P. 2013. Do we need continuous glucose monitoring in type 2 diabetes? Diabetes Metab. Res. Rev. doi: 10.1002/dmrr.2450
146. Mazze RS, Strock E,Wesley D, Borgman S, Morgan B, et al. 2008. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol. Ther. 10:149-59
147. McCarter RJ, Hempe JM, Chalew SA. 2006. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 29:352-55
148. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. 2005. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol. Ther. 7:253-63
149. Meigs JB, Nathan DM, D Agostino RB Sr, Wilson PW, Framingham Offspring S. 2002. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845-50
150. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, et al. 1990. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381-90
151. Moberg EA, Lins PE, Adamson UK. 1994. Variability of blood glucose levels in patients with type 1 diabetes mellitus on intensified insulin regimens. Diabetes Metab. 20:546-52
152. Molnar GD, Taylor WF, Ho MM. 1972. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 8:342-48
153. Monnier L, Colette C. 2008. Glycemic variability: Should we and can we prevent it? Diabetes Care 31(Suppl. 2):S150-54
154. Monnier L, Colette C, Dunseath GJ, Owens DR. 2007. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30:263-69
155. Monnier L, Colette C, Lapinski H. 2004. Global assessment for quality and safety of control in type 2 diabetic patients. Eur. J. Clin. Invest. 34:37-42
156. Monnier L, Colette C, MasE,Michel F, Cristol JP, et al. 2010. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 53:562-71
157. Monnier L, Lapinski H, Colette C. 2003. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26:881-85
158. Monnier L, Mas E, Ginet C, Michel F, Villon L, et al. 2006. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-87
159. Monnier L, Wojtusciszyn A, Colette C, Owens D. 2011. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol. Ther. 13:813-18
160. Mori Y, Ohta T, ShiozakiM, Yokoyama J, Utsunomiya K. 2012. The effect of a low-carbohydrate/highmonounsaturated fatty acid liquid diet and an isoleucine-containing liquid diet on 24-h glycemic variability in diabetes patients on tube feeding: a comparison by continuous glucose monitoring. Diabetes Technol. Ther. 14:619-23
161. Mori Y, Ohta T, Yokoyama J, Utsunomiya K. 2013. Effects of low-carbohydrate/high-monounsaturated fatty acid liquid diets on diurnal glucose variability and insulin dose in type 2 diabetes patients on tube feeding who require insulin therapy. Diabetes Technol. Ther. 15:762-67
162. Muggeo M, Verlato G, Bonora E, Ciani F, Moghetti P, et al. 1995. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia 38:672-79
163. MuggeoM, Verlato G, Bonora E, Zoppini G, CorbelliniM, deMarco R. 1997. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulindependent diabetes mellitus: the Verona Diabetes Study. Circulation 96:1750-54
164. MuggeoM, Zoppini G, Bonora E, Brun E, Bonadonna RC, et al. 2000. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 23:45-50
165. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. 2010. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes. Metab. 12:288-98
166. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, et al. 2002. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J. Am. Coll. Cardiol. 39:1145-50
167. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. 2005. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353:2643-53
168. Navig. Study Group, Holman RR, Haffner SM,McMurray JJ, BethelMA,et al. 2010. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362:1463-76
169. NICE-SUGAR Study Investig., Finfer S, Chittock DR, Su SY, Blair D, et al. 2009. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 360:1283-97
170. Nilsson M, Stenberg M, Frid AH, Holst JJ, Bj orck IM. 2004. Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am. J. Clin. Nutr. 80:1246-53
171. O Keefe JH, Gheewala NM, O Keefe JO. 2008. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J. Am. Coll. Cardiol. 51:249-55
172. O Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. 1999. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340:14-22
173. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, et al. 1995. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28:103-17
174. Paddon-Jones D, WestmanE,MattesRD, Wolfe RR, AstrupA,Westerterp-PlantengaM. 2008. Protein, weight management, and satiety. Am. J. Clin. Nutr. 87:1558-61S
175. Patrono C, Falco A, Davi G. 2005. Isoprostane formation and inhibition in atherothrombosis. Curr. Opin. Pharmacol. 5:198-203
176. Pearce KL, Noakes M, Keogh J, Clifton PM. 2008. Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes. Am. J. Clin. Nutr. 87:638-44
177. Petersen BL,WardLS, Bastian ED, Jenkins AL,Campbell J, Vuksan V. 2009.Awhey protein supplement decreases post-prandial glycemia. Nutr. J. 8:47
178. Piconi L, Quagliaro L, Assaloni R, Da Ros R, Maier A, et al. 2006. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab. Res. Rev. 22:198-203
179. Pratley RE, Weyer C. 2001. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44:929-45
180. Proudfoot J, Barden A, Mori TA, Burke V, Croft KD, et al. 1999. Measurement of urinary F2-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal. Biochem. 272:209-15
181. Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, et al. 2000. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 43:1470-75
182. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. 2003. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52:2795-804
183. Raz I, Ceriello A, Wilson PW, Battioui C, Su EW, et al. 2011. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care 34:1511-13
184. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, et al. 2009. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381-86
185. RiddleM, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. 2011. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 34:2508-14
186. Rizzo MR, BarbieriM,Marfella R, Paolisso G. 2012. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35:2076-82
187. Rodbard D. 2009. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol. Ther. 11:551-65
188. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. 2002. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 25:275-78
189. Rosenstock J, HassmanDR, MadderRD, Brazinsky SA, Farrell J, et al. 2004. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27:1265-70
190. Saeed A, Jones SA, Nuttall FQ,GannonMC. 2002. A fasting-induced decrease in plasma glucose concentration does not affect the insulin response to ingested protein in people with type 2 diabetes. Metabolism 51:1027-33
191. Salehi A, GunnerudU,Muhammed SJ, Ostman E,Holst JJ, et al. 2012. The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on β-cells. Nutr. Metab. (Lond.) 9:48
192. Sartore G, Chilelli NC, Burlina S, Di Stefano P, Piarulli F, et al. 2012. The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucosemonitoring (CGM). Acta Diabetol. 49(Suppl. 1):S153-60
193. Schlichtkrull J, Munck O, Jersild M. 1965. The M-valve, an index of blood-sugar control in diabetics. Acta Med. Scand. 177:95-102
194. Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. 2006. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 29:95-100
195. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, et al. 2004. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 141:421-31
196. Service FJ. 1990. Correlation between glycemia and glycated hemoglobin. Compr. Ther. 16:33-40
197. Service FJ,Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, TaylorWF. 1970. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644-55
198. Service FJ, O Brien PC. 2001. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 44:1215-20
199. Service FJ,O Brien PC. 2007. Influence of glycemic variables on hemoglobin A1c. Endocr. Pract. 13:350-54
200. Service FJ, O Brien PC, Rizza RA. 1987. Measurements of glucose control. Diabetes Care 10:225-37
201. Sheard NF, Clark NG, Brand-Miller JC, Franz MJ, Pi-Sunyer FX, et al. 2004. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the American Diabetes Association. Diabetes Care 27:2266-71
202. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. 2000. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23(Suppl. 2):B21-29
203. Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, et al. 2005. Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 28:2806-7
204. Siegelaar SE, Barwari T, Kulik W, Hoekstra JB, DeVries JH. 2011. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J. Diabetes Sci. Technol. 5:86-92
205. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. 2010. Glucose variability; does it matter? Endocr. Rev. 31:171-82
206. Siegelaar SE, Kerr L, Jacober SJ, Devries JH. 2011. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 34:855-57
207. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JB, Devries JH. 2009. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52:2229-32
208. Siegelaar SE, Kulik W, van Lenthe H, Mukherjee R, Hoekstra JB, Devries JH. 2009. A randomized clinical trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress. Diabetes Obes. Metab. 11:709-14
209. Sircar D, Subbaiah PV. 2007. Isoprostane measurement in plasma and urine by liquid chromatography-mass spectrometry with one-step sample preparation. Clin. Chem. 53:251-58
210. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W. 1999. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res. Clin. Pract. 46:23-27
211. Sorkin JD, Muller DC, Fleg JL, Andres R. 2005. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 28:2626-32
212. Standl E, Schnell O, Ceriello A. 2011. Postprandial hyperglycemia and glycemic variability: Should we care? Diabetes Care 34(Suppl. 2):S120-27
213. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al. 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-12
214. Su G, Mi S, Tao H, Li Z, Yang H, et al. 2011. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc. Diabetol. 10:19
215. Su G, Mi SH, Tao H, Li Z, Yang HX, et al. 2013. Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care 36:1026-32
216. Sugawara A, Kawai K, Motohashi S, Saito K, Kodama S, et al. 2012. HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia 55:2128-31
217. Tahara Y, Shima K. 1993. The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 16:1313-14
218. Takao T, Ide T, Yanagisawa H, KikuchiM, Kawazu S, Matsuyama Y. 2010. The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term followup. Diabetes Res. Clin. Pract. 89:296-302
219. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, et al. 2014. A very low carbohydrate, low saturated fat diet for type 2 diabetes management: a randomized trial. Diabetes Care 37:2909-18
220. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. 2000. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23:1830-34
221. The DECODE study group on behalf of Eur. on Diabetes Epidemiol. Group. 1999. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-21
222. The Diabetes Control Complicat. Trial Res. Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:977-86
223. The Diabetes Control Complicat. Trial Res. Group. 1995. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44:968-83
224. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. 1999. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-24
225. Trovati M, Burzacca S, Mularoni E, Massucco P, Cavalot F, et al. 1991. Occurrence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycaemic agents: importance of blood glucose monitoring. Diabetologia 34:662-67
226. Tsujino D, Nishimura R, Taki K, Miyashita Y, Morimoto A, Tajima N. 2009. Daily glucose profiles in Japanese people with normal glucose tolerance as assessed by continuous glucose monitoring. Diabetes Technol. Ther. 11:457-60
227. UK Prospect. Diabetes Study Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-53
228. Waden J, ForsblomC,Thorn LM,GordinD, Saraheimo M, et al. 2009. A1C variability predicts incident cardiovascular events,microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649-55
229. Wang X, Zhao X, Dorje T, Yan H, Qian J, Ge J. 2014. Glycemic variability predicts cardiovascular complications in acute myocardial infarction patients with type 2 diabetes mellitus. Int. J. Cardiol. 172:498-500
230. Wentholt IM,Kulik W, MichelsRP, Hoekstra JB,DeVries JH. 2008. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 51:183-90
231. Wilson PW, D Agostino RB, Sullivan L, Parise H, Kannel WB. 2002. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 162:1867-72
232. Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kache S, Wilson DM. 2006. Association of hypoglycemia, hyperglycemia, and glucose variability withmorbidity and death in the pediatric intensive care unit. Pediatrics 118:173-79
233. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, et al. 2007. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res. Clin. Pract. 77:280-85
234. Wojcicki JM. 1995. "J"-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm. Metab. Res. 27:41-42
235. Wolever TM, Jenkins DJ. 1986. The use of the glycemic index in predicting the blood glucose response to mixed meals. Am. J. Clin. Nutr. 43:167-72
236. WoleverTM,MehlingC. 2003. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am. J. Clin. Nutr. 77:612-21
237. Wong VW, McLean M, Boyages SC, Cheung NW. 2004. C-reactive protein levels following acute myocardial infarction: effect of insulin infusion and tight glycemic control. Diabetes Care 27:2971-73
238. Woo V, Shestakova MV, Orskov C, Ceriello A. 2008. Targets and tactics: the relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes. Int. J. Clin. Pract. 62:1935-42
239. Yokoyama H, Kannno S, Ishimura I,Node K. 2007. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. Metabolism 56:1458-63
240. Zoppini G, Verlato G, Targher G, Bonora E, Trombetta M, Muggeo M. 2008. Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. Diabetes Metab. Res. Rev. 24:624-28
241. Zoppini G, Verlato G, Targher G, Casati S, Gusson E, et al. 2009. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? Nutr. Metab. Cardiovasc. Dis. 19:334-39